St Herblain

• A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep … Ended recruitment
  2023-506717-21-00 9 2024-10-02 Breast Cancer
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended recruitment
  2023-504922-20-00 5 2024-08-23 Hypercholesterolemia
• A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small … Ended recruitment
  2023-508256-19-00 9 2024-07-15 Unresectable Metastatic Non-small Cell Lung Cancer
• AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT … Ended recruitment
  2023-508130-33-00 9 2024-07-03 ADVANCED OR METASTATIC BREAST CANCER
• A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Ended recruitment
  2023-506228-10-00 7 2024-06-27 Pancreatic Ductal Adenocarcinoma
• A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs ar … Ended recruitment
  2023-508459-37-00 1 2024-05-28 HER2-positive advanced solid tumours
• A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca … Ended recruitment
  2023-507995-33-00 9 2024-05-23 MSI-H/dMMR Gastric cancer
• A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended recruitment
  2023-507333-17-00 5 2024-04-15 HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended recruitment
  2022-502010-85-00 9 2023-12-20 Non-Squamous Non-Small Cell Lung Cancer
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M … Ended recruitment
  2022-502975-45-00 5 2023-12-12 Metastatic leiomyosarcoma
• SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH … Ended recruitment
  2023-507672-52-00 7 2023-11-07 PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Un … Ended recruitment
  2023-505211-21-00 4 2023-03-10 Previously untreated locally advanced or metastatic non-small cell lun
• An Open-Label Phase 1/2 Trial to Evaluate the Safety, Tolerability, and Efficacy of MORAb 202 in Subjects with Selected Tumor Types. Ended recruitment
  2023-506868-14-00 9 2023-02-28 Solid tumors in 4 tumor types: platinum resistant ovarian cancer, trip
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie … Ended recruitment
  2022-501493-19-00 5 2023-02-20 metastatic Castration-Resistant Prostate Cancer (mCRPC)
• DARIUS : A randomized non-comparative phase II multicentric trial on short term DARolutamide (ODM-201) concomitant to radiation therapy for … Ended recruitment
  2023-509494-23-00 4 2023-02-20 Adult patients with intermediate unfavorable risk prostate cancer as p
• A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an … Ended recruitment
  2023-508265-33-00 5 2022-10-13 Vasomotor symptoms caused by adjuvant endocrine therapy in women with,
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• Binimetinib, Encorafenib and Pembrolizumab COmbination in MElanoma - Metastatic to the Brain Ended recruitment
  2023-505302-42-00 4 2022-09-05 BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)
• Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF … Ended recruitment
  2023-507964-38-00 5 2022-09-01 Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot … Ended recruitment
  2023-510387-13-00 4 2022-05-18 advanced ALK-positive non-small cell lung cancer

Showing 49–72 of 118 trials